181 related articles for article (PubMed ID: 36499459)
1. Functional Effects of Epilepsy Associated
Rychkov GY; Shaukat Z; Lim CX; Hussain R; Roberts BJ; Bonardi CM; Rubboli G; Meaney BF; Whitney R; Møller RS; Ricos MG; Dibbens LM
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499459
[TBL] [Abstract][Full Text] [Related]
2. An Epilepsy-Associated KCNT1 Mutation Enhances Excitability of Human iPSC-Derived Neurons by Increasing Slack K
Quraishi IH; Stern S; Mangan KP; Zhang Y; Ali SR; Mercier MR; Marchetto MC; McLachlan MJ; Jones EM; Gage FH; Kaczmarek LK
J Neurosci; 2019 Sep; 39(37):7438-7449. PubMed ID: 31350261
[TBL] [Abstract][Full Text] [Related]
3. Disease-causing Slack potassium channel mutations produce opposite effects on excitability of excitatory and inhibitory neurons.
Wu J; Quraishi IH; Zhang Y; Bromwich M; Kaczmarek LK
Cell Rep; 2024 Mar; 43(3):113904. PubMed ID: 38457342
[TBL] [Abstract][Full Text] [Related]
4. Functional evaluation of epilepsy-associated KCNT1 variants in multiple cellular systems reveals a predominant gain of function impact on channel properties.
Hinckley CA; Zhu Z; Chu JH; Gubbels C; Danker T; Cherry JJ; Whelan CD; Engle SJ; Nguyen V
Epilepsia; 2023 Aug; 64(8):2126-2136. PubMed ID: 37177976
[TBL] [Abstract][Full Text] [Related]
5. The Functional Properties, Physiological Roles, Channelopathy and Pharmacological Characteristics of the Slack (KCNT1) Channel.
Zhang Q; Liu Y; Xu J; Teng Y; Zhang Z
Adv Exp Med Biol; 2021; 1349():387-400. PubMed ID: 35138624
[TBL] [Abstract][Full Text] [Related]
6. KCNT1-related epilepsies and epileptic encephalopathies: phenotypic and mutational spectrum.
Bonardi CM; Heyne HO; Fiannacca M; Fitzgerald MP; Gardella E; Gunning B; Olofsson K; Lesca G; Verbeek N; Stamberger H; Striano P; Zara F; Mancardi MM; Nava C; Syrbe S; Buono S; Baulac S; Coppola A; Weckhuysen S; Schoonjans AS; Ceulemans B; Sarret C; Baumgartner T; Muhle H; Portes VD; Toulouse J; Nougues MC; Rossi M; Demarquay G; Ville D; Hirsch E; Maurey H; Willems M; de Bellescize J; Altuzarra CD; Villeneuve N; Bartolomei F; Picard F; Hornemann F; Koolen DA; Kroes HY; Reale C; Fenger CD; Tan WH; Dibbens L; Bearden DR; Møller RS; Rubboli G
Brain; 2021 Dec; 144(12):3635-3650. PubMed ID: 34114611
[TBL] [Abstract][Full Text] [Related]
7. K
Gertler TS; Cherian S; DeKeyser JM; Kearney JA; George AL
Neurobiol Dis; 2022 Jun; 168():105713. PubMed ID: 35346832
[TBL] [Abstract][Full Text] [Related]
8. Potassium channelopathies associated with epilepsy-related syndromes and directions for therapeutic intervention.
Gribkoff VK; Winquist RJ
Biochem Pharmacol; 2023 Feb; 208():115413. PubMed ID: 36646291
[TBL] [Abstract][Full Text] [Related]
9. Drosophila expressing mutant human KCNT1 transgenes make an effective tool for targeted drug screening in a whole animal model of KCNT1-epilepsy.
Hussain R; Lim CX; Shaukat Z; Islam A; Caseley EA; Lippiat JD; Rychkov GY; Ricos MG; Dibbens LM
Sci Rep; 2024 Feb; 14(1):3357. PubMed ID: 38336906
[TBL] [Abstract][Full Text] [Related]
10. Two Patients With KCNT1-Related Epilepsy Responding to Phenobarbital and Potassium Bromide.
Datta AN; Michoulas A; Guella I; ; Demos M
J Child Neurol; 2019 Oct; 34(12):728-734. PubMed ID: 31208268
[No Abstract] [Full Text] [Related]
11. Reduced GABAergic Neuron Excitability, Altered Synaptic Connectivity, and Seizures in a KCNT1 Gain-of-Function Mouse Model of Childhood Epilepsy.
Shore AN; Colombo S; Tobin WF; Petri S; Cullen ER; Dominguez S; Bostick CD; Beaumont MA; Williams D; Khodagholy D; Yang M; Lutz CM; Peng Y; Gelinas JN; Goldstein DB; Boland MJ; Frankel WN; Weston MC
Cell Rep; 2020 Oct; 33(4):108303. PubMed ID: 33113364
[TBL] [Abstract][Full Text] [Related]
12. Disease-causing Slack potassium channel mutations produce opposite effects on excitability of excitatory and inhibitory neurons.
Wu J; Quraishi IH; Zhang Y; Bromwich M; Kaczmarek LK
bioRxiv; 2023 Feb; ():. PubMed ID: 36824888
[TBL] [Abstract][Full Text] [Related]
13. An ALS-Associated Mutant SOD1 Rapidly Suppresses KCNT1 (Slack) Na
Zhang Y; Ni W; Horwich AL; Kaczmarek LK
J Neurosci; 2017 Feb; 37(8):2258-2265. PubMed ID: 28119399
[TBL] [Abstract][Full Text] [Related]
14. Approaches for the discovery of drugs that target K Na 1.1 channels in KCNT1-associated epilepsy.
Miziak B; Czuczwar SJ
Expert Opin Drug Discov; 2022 Dec; 17(12):1313-1328. PubMed ID: 36408599
[TBL] [Abstract][Full Text] [Related]
15. Utilising Automated Electrophysiological Platforms in Epilepsy Research.
Milligan CJ; Pachernegg S
Methods Mol Biol; 2021; 2188():133-155. PubMed ID: 33119850
[TBL] [Abstract][Full Text] [Related]
16.
Iraci N; Carotenuto L; Ciaglia T; Belperio G; Di Matteo F; Mosca I; Carleo G; Giovanna Basilicata M; Ambrosino P; Turcio R; Puzo D; Pepe G; Gomez-Monterrey I; Soldovieri MV; Di Sarno V; Campiglia P; Miceli F; Bertamino A; Ostacolo C; Taglialatela M
J Med Chem; 2024 Jun; 67(11):9124-9149. PubMed ID: 38782404
[TBL] [Abstract][Full Text] [Related]
17. Impaired motor skill learning and altered seizure susceptibility in mice with loss or gain of function of the Kcnt1 gene encoding Slack (K
Quraishi IH; Mercier MR; McClure H; Couture RL; Schwartz ML; Lukowski R; Ruth P; Kaczmarek LK
Sci Rep; 2020 Feb; 10(1):3213. PubMed ID: 32081855
[TBL] [Abstract][Full Text] [Related]
18. In silico model reveals the key role of GABA in KCNT1-epilepsy in infancy with migrating focal seizures.
Kuchenbuch M; Nabbout R; Yochum M; Sauleau P; Modolo J; Wendling F; Benquet P
Epilepsia; 2021 Mar; 62(3):683-697. PubMed ID: 33617692
[TBL] [Abstract][Full Text] [Related]
19. The Phe932Ile mutation in KCNT1 channels associated with severe epilepsy, delayed myelination and leukoencephalopathy produces a loss-of-function channel phenotype.
Evely KM; Pryce KD; Bhattacharjee A
Neuroscience; 2017 May; 351():65-70. PubMed ID: 28366665
[TBL] [Abstract][Full Text] [Related]
20. New use for an old drug: quinidine in KCNT1-related epilepsy therapy.
Liu R; Sun L; Wang Y; Wang Q; Wu J
Neurol Sci; 2023 Apr; 44(4):1201-1206. PubMed ID: 36437393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
